The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus
Not Applicable
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-UMIN000011137
- Lead Sponsor
- Department of Metabolic Medicine Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Patient whom beraprost sodium is contraindicated for Patient who takes vasodilator (nitrates) Patinet who has been started anitiplatelet drugs and/or drugs for dyslipidemia within 3 months before starting beraprost sodium Patinet who have been changed drugs for diabetes mellitus within 3 months before starting beraprost sodium Patient whose ABI is less than 0.9 Patinet who take glucocorticoids and NSAID (except aspirin) Patient who has the impairment of renal function (Cr more than 2 mg/dl) Patient who is unsuitable for this study (judged by a doctor)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Atherosclerosis, glucose metabolism, diabetic nephropathy, QO
- Secondary Outcome Measures
Name Time Method